8/103 sources · 3 publishersUpdated Oct 8, 17:35 UTC
Health Canada clears Lipocine’s oral testosterone therapy for Canadian market
Health Canada authorized Lipocine's TLANDO capsules for testosterone replacement in adult men with hypogonadism. Lipocine's North American licensee, Verity Pharmaceuticals, is preparing a Canadian rollout before 2026 ends. TLANDO is a fixed-dose oral option that does not need dose titration.
Why it matters
The decision removes the Canadian regulatory barrier for TLANDO, while Verity Pharmaceuticals remains responsible for bringing it to market. Lipocine says Canada records more than 700,000 annual prescriptions for testosterone replacement therapy, but it gave no Canadian sales or market-share forecast.
Key facts
- 1Health Canada authorized TLANDO for testosterone replacement therapy in adult males with hypogonadism. investing.com
- 2Verity Pharmaceuticals holds exclusive North American commercial rights to TLANDO and expects to introduce it in Canada before the close of 2026. investing.com
- 3TLANDO contains testosterone undecanoate in 112.5mg capsules for oral use. investing.com
- 4Lipocine and Verity Pharmaceuticals signed their exclusive United States and Canada licensing agreement in January 2024. investing.com
- 5Lipocine says more than 700,000 prescriptions for testosterone replacement therapy are issued each year in Canada. finance.yahoo.com
Open questions
- Lipocine did not disclose expected Canadian sales, market share, or the financial contribution from TLANDO's Canadian launch.
Summary written by AlphAI from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.